Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACRS | Aclaris Therapeutics, Inc.

Healthcare | Diagnostics & Research | USA | NASD

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	0.20%	Shs Outstand	70.63M	Perf Week	-14.75%
Market Cap	511.64M	Forward P/E	-	EPS next Y	-1.86	Insider Trans	8.85%	Shs Float	64.88M	Perf Month	-9.55%
Income	-105.30M	PEG	-	EPS next Q	-0.48	Inst Own	96.50%	Short Float / Ratio	8.79% / 8.11	Perf Quarter	-33.33%
Sales	31.20M	P/S	16.40	EPS this Y	16.80%	Inst Trans	0.38%	Short Interest	5.70M	Perf Half Y	-13.67%
Book/sh	2.54	P/B	2.69	EPS next Y	-3.90%	ROA	-42.70%	Target Price	31.14	Perf Year	-52.27%
Cash/sh	1.60	P/C	4.27	EPS next 5Y	-	ROE	-54.40%	52W Range	5.77 - 18.96	Perf YTD	-56.70%
Dividend	-	P/FCF	-	EPS past 5Y	11.80%	ROI	-45.50%	52W High	-64.03%	Beta	0.68
Dividend %	-	Quick Ratio	5.80	Sales past 5Y	77.60%	Gross Margin	57.70%	52W Low	18.20%	ATR	0.48
Employees	105	Current Ratio	5.80	Sales Q/Q	26.70%	Oper. Margin	-	RSI (14)	35.21	Volatility	7.39% 6.75%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-34.50%	Profit Margin	-	Rel Volume	1.18	Prev Close	6.77
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	Payout	-	Avg Volume	702.83K	Price	6.82
Recom	1.40	SMA20	-8.65%	SMA50	-20.41%	SMA200	-36.55%	Volume	831,490	Change	0.74%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-22	Initiated	Stifel	Buy	$29
Dec-01-22	Initiated	Goldman	Buy	$25
Oct-06-22	Initiated	BTIG Research	Buy	$32
Jul-23-21	Resumed	Jefferies	Buy	$27 → $32
Jun-15-21	Initiated	Piper Sandler	Overweight	$30
Apr-21-21	Initiated	H.C. Wainwright	Buy	$40
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform	$13
Mar-28-18	Resumed	Leerink Partners	Outperform	$52
Feb-09-18	Initiated	Guggenheim	Buy	$53
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight	$50
Nov-29-16	Initiated	Leerink Partners	Outperform	$54
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy	$35
Nov-02-15	Initiated	Jefferies	Buy	$20
Nov-02-15	Initiated	Citigroup	Buy

Show Previous Ratings

Sep-20-23 07:00AM	Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -8.51%
Sep-18-23 07:00AM	Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor (GlobeNewswire)
Sep-14-23 07:03PM	Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday (Motley Fool) +5.54%
Sep-08-23 05:06PM	Insider Buying: CFO Kevin Balthaser Acquires 9,490 Shares of Aclaris Therapeutics Inc (GuruFocus.com)
Aug-10-23 06:07AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
08:40AM	Loading…
Aug-08-23 08:40AM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11% (Simply Wall St.) -5.25%
Aug-07-23 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -7.21%
07:10AM	Aclaris: Q2 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-01-23 07:53AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 363% gain (Simply Wall St.)
Jul-06-23 08:19AM	Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last? (Zacks)
Jun-26-23 10:15AM	2 Low-Priced Stocks That Could Make You Richer (Motley Fool)
Jun-13-23 06:30PM	Why Aclaris Therapeutics Topped the Market on Tuesday (Motley Fool)
07:01AM	Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202) (GlobeNewswire)
Jun-02-23 07:00AM	Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences (GlobeNewswire)
01:50PM	Loading…
May-18-23 01:50PM	Top Pharmaceutical Stocks for Q2 2023 (Investopedia)
May-10-23 06:04AM	Aclaris Therapeutics First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-08-23 11:55PM	Q1 2023 Aclaris Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.46%
08:15AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Aclaris: Q1 Earnings Snapshot (AP Finance)
07:00AM	Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-05-23 06:49AM	What Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) P/S Is Not Telling You (Simply Wall St.)
May-02-23 07:01AM	Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023 (GlobeNewswire)
Apr-27-23 04:35AM	Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? (Zacks)
Apr-24-23 02:37PM	3 Biotech Stocks to Sell Before Theyre 6 Feet Under (InvestorPlace)
Apr-04-23 07:40AM	Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation (Simply Wall St.)
Mar-27-23 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-10-23 11:34AM	Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds (American City Business Journals)
Mar-06-23 03:59PM	As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris (Benzinga) -44.68%
02:32PM	These 2 Biotech Stocks Made Big Monday Moves (Motley Fool)
01:03PM	Loading…
01:03PM	Why Aclaris Therapeutics Stock Is Plunging Today (Benzinga)
11:50AM	Why Aclaris Therapeutics Is Crashing Today (Motley Fool)
07:00AM	Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa (GlobeNewswire)
Feb-23-23 08:35AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-23 06:01AM	Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 943% gain (Simply Wall St.)
Feb-09-23 04:01PM	Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-06-23 07:01AM	Aclaris Therapeutics Provides 2023 Outlook (GlobeNewswire) +8.67%
Nov-29-22 07:00AM	Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China (GlobeNewswire) -7.06%
Nov-26-22 01:39PM	Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine (American City Business Journals)
Nov-22-22 04:01PM	Aclaris Therapeutics Announces Key Leadership Transitions (GlobeNewswire)
Nov-16-22 12:10PM	Aclaris Therapeutics Looks Promising on the Charts (TheStreet.com)
Nov-10-22 04:01PM	Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences (GlobeNewswire)
Nov-08-22 08:25AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-26-22 06:44AM	We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely (Simply Wall St.)
Sep-27-22 07:00AM	Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations (GlobeNewswire)
Sep-15-22 06:46AM	Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 years (Simply Wall St.)
Aug-30-22 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-25-22 07:00AM	Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata (GlobeNewswire) +5.26%
Aug-05-22 07:59AM	Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt? (Simply Wall St.) +7.33%
Aug-03-22 08:25AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-01-22 07:00AM	Aclaris Therapeutics Expands Leadership Team (GlobeNewswire) -11.62%
Jul-15-22 12:00PM	Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy (Zacks)
Jul-08-22 09:40AM	Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-01-22 09:36AM	Lab Notes: Verrica continues push for skin disorder drug, raising $25M; Windtree weighing options (American City Business Journals)
Jun-27-22 07:00AM	Aclaris Therapeutics Expands Leadership Team (GlobeNewswire)
Jun-22-22 09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-20-22 08:20AM	Aclaris (ACRS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Jun-13-22 09:55AM	Does Aclaris (ACRS) Have the Potential to Rally 141% as Wall Street Analysts Expect? (Zacks) -10.39%
Jun-06-22 09:40AM	Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year? (Zacks)
Jun-01-22 04:01PM	Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-27-22 09:55AM	Wall Street Analysts Believe Aclaris (ACRS) Could Rally 179%: Here's is How to Trade (Zacks)
May-17-22 11:53AM	KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M (Zacks) +11.70%
May-16-22 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-10-22 08:15AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-04-22 07:35PM	Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
May-03-22 07:00AM	Aclaris Therapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium (GlobeNewswire)
May-02-22 06:10AM	We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely (Simply Wall St.) +5.11%
Apr-13-22 12:17AM	FEC Resources Reports on SC 72 Force Majeure Declaration (Newsfile)
Feb-24-22 08:55AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.22%
07:00AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-21-22 04:34AM	Those who invested in Aclaris Therapeutics (NASDAQ:ACRS) three years ago are up 97% (Simply Wall St.)
Feb-17-22 03:03PM	Earnings Preview: Aclaris Therapeutics (ACRS) Q4 Earnings Expected to Decline (Zacks)
Feb-06-22 04:33PM	Did Hedge Funds Catch A Break With Aclaris Therapeutics, Inc. (ACRS)? (Insider Monkey)
Feb-02-22 07:00AM	Aclaris Therapeutics to Participate in the SVB Leerink Virtual 11th Annual Global Healthcare Conference (GlobeNewswire)
Feb-01-22 04:01PM	Aclaris Therapeutics Expands Leadership Team (GlobeNewswire) +6.04%
Jan-11-22 04:01PM	Aclaris Therapeutics Provides R&D Update (GlobeNewswire)
Dec-27-21 07:00AM	Aclaris Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-20-21 05:21PM	Top Biotech Stocks for Q4 2021 (Investopedia)
Dec-08-21 11:59AM	Is Aclaris Therapeutics, Inc. (ACRS) Going to Burn These Hedge Funds? (Insider Monkey)
Dec-03-21 07:00AM	Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine (GlobeNewswire)
Nov-23-21 04:13AM	Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation (Simply Wall St.) -6.11%
Nov-18-21 04:01PM	Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021 (GlobeNewswire)
Nov-03-21 07:00AM	Aclaris Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-02-21 08:25AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -10.87%
07:00AM	Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-27-21 03:03PM	Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-12-21 07:16PM	Hedge Funds Are Crazy About Aclaris Therapeutics, Inc. (ACRS) (Insider Monkey)
Sep-29-21 08:47AM	15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Sep-20-21 08:00AM	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aclaris Therapeutics, Inc. ACRS (GlobeNewswire) -6.94%
Aug-26-21 04:01PM	Aclaris Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-21 06:16AM	The 9.4% return this week takes Aclaris Therapeutics' (NASDAQ:ACRS) shareholders one-year gains to 510% (Simply Wall St.)
Aug-05-21 10:58AM	Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings? (Zacks)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-21 03:00PM	Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-08-21 07:00AM	Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jul-06-21 11:49AM	10 Best Pharmaceutical Stocks to Buy According to Billionaire Joseph Edelman (Insider Monkey)

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Balthaser Kevin	Chief Financial Officer	Sep 06	Buy	7.90	9,490	74,971	15,461	Sep 07 04:16 PM
Loerop James	Chief Business Officer	Aug 28	Buy	6.80	14,705	99,959	21,688	Aug 28 04:39 PM
Monahan Joseph	Chief Scientific Officer	Aug 21	Sale	7.32	6,000	43,895	135,724	Aug 22 04:31 PM
Molineaux Christopher P.	Director	Jun 20	Option Exercise	1.41	16,500	23,265	48,503	Jun 22 04:32 PM
Monahan Joseph	Chief Scientific Officer	Jun 20	Sale	10.28	6,000	61,663	141,724	Jun 22 04:30 PM
Molineaux Christopher P.	Director	Jun 15	Option Exercise	1.36	249	338	32,003	Jun 20 04:31 PM
Manion Douglas J.	Pres and CEO	Mar 17	Buy	7.86	6,300	49,532	12,800	Mar 17 05:03 PM
Manion Douglas J.	Pres and CEO	Mar 09	Buy	7.74	6,500	50,278	6,500	Mar 09 05:56 PM
Walker Neal	Director	Mar 03	Sale	12.63	30,240	382,070	1,273,202	Mar 03 08:37 PM
Monahan Joseph	Chief Scientific Officer	Mar 03	Sale	12.63	16,037	202,615	147,724	Mar 03 08:12 PM
Balthaser Kevin	Chief Financial Officer	Mar 03	Sale	12.63	894	11,290	5,256	Mar 03 08:09 PM
Walker Neal	Director	Mar 02	Sale	12.37	29,000	358,588	1,285,188	Mar 03 08:37 PM
Monahan Joseph	Chief Scientific Officer	Mar 02	Sale	12.37	14,800	183,024	151,261	Mar 03 08:12 PM
Balthaser Kevin	Chief Financial Officer	Mar 02	Sale	12.29	1,000	12,289	4,650	Mar 03 08:09 PM
Monahan Joseph	Chief Scientific Officer	Feb 15	Sale	13.06	5,000	65,310	91,386	Feb 17 04:34 PM
Loerop James	Chief Business Officer	Feb 08	Sale	13.89	4,267	59,272	6,983	Feb 10 04:55 PM
Walker Neal	Director	Feb 02	Sale	16.25	5,000	81,248	1,175,763	Feb 03 05:09 PM
Walker Neal	Director	Feb 01	Sale	16.75	25,000	418,675	1,180,763	Feb 03 05:09 PM
Walker Neal	Director	Jan 04	Sale	14.89	15,000	223,342	1,205,763	Jan 04 06:20 PM
Walker Neal	Director	Jan 03	Sale	15.25	25,000	381,213	1,220,763	Jan 04 06:20 PM
Monahan Joseph	Chief Scientific Officer	Dec 15	Sale	15.88	5,000	79,412	96,386	Dec 16 04:57 PM
SCHIFF ANDREW N	Director	Nov 14	Sale	17.08	1,371	23,417	434,455	Nov 14 04:51 PM
SCHIFF ANDREW N	Director	Nov 11	Sale	17.06	41,160	702,177	435,826	Nov 14 04:51 PM
SCHIFF ANDREW N	Director	Nov 10	Sale	17.02	11,395	193,995	476,986	Nov 14 04:51 PM
SCHIFF ANDREW N	Director	Oct 26	Sale	17.00	14,540	247,253	488,381	Oct 26 07:09 PM
SCHIFF ANDREW N	Director	Oct 25	Sale	17.02	12,018	204,516	502,921	Oct 26 07:09 PM
SCHIFF ANDREW N	Director	Oct 24	Sale	17.01	14,616	248,586	514,939	Oct 26 07:09 PM
SCHIFF ANDREW N	Director	Oct 18	Sale	16.89	32,093	542,022	529,555	Oct 19 04:49 PM
SCHIFF ANDREW N	Director	Oct 17	Sale	16.05	19,944	320,087	561,648	Oct 19 04:49 PM
Monahan Joseph	Chief Scientific Officer	Oct 17	Sale	15.98	5,000	79,908	101,386	Oct 19 04:45 PM
SCHIFF ANDREW N	Director	Oct 07	Sale	16.16	7,324	118,349	581,592	Oct 11 04:35 PM
SCHIFF ANDREW N	Director	Oct 06	Sale	16.54	37,839	625,744	588,916	Oct 06 05:58 PM
SCHIFF ANDREW N	Director	Oct 04	Sale	16.01	7,700	123,259	626,755	Oct 06 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACRS | Aclaris Therapeutics, Inc.

Upgrade your FINVIZ experience